By Kamal Choudhury March 16 (Reuters) - Rhythm Pharmaceuticals said on Monday its experimental obesity drug in patients with rare genetic conditions did not meet the main goal of a late-stage trial.

Whether happening in public or private, biopharma M&A is fiercer than ever. Experts point to patent pressures, herd mentality ...

NRx Pharmaceuticals Inc. NRXP shares are surging on Monday following positive developments regarding its New Drug Application ...

Gesynta Pharma has dosed the first patient in its Phase II trial, NOVA, investigating vipoglanstat, a non-hormonal, ...

Middle East war disrupts pharma routes, threatening refrigerated cancer drug supplies to Gulf as hubs shut and shipments reroute.

Astellas Pharma has awarded its healthcare provider (HCP) and direct-to-consumer (DTC) business to CMI Media Group, Compas and WPP Media, the drugmaker confirmed Monday afternoon. According to ...

Rapid Micro Biosystems, Inc. sees strong FY25 revenue growth from Growth Direct placements, but losses persist. Click for ...

Pharma companies are leveraging the United States’ threat of tariffs on drug imports to push for policy changes in the EU. In a letter sent to European Commission President Ursula von der Leyen, 32 ...

Coriolis Pharma, a global contract research and development organization, celebrated the grand opening of its new North America headquarters and laboratory, marking the start of operations at the ...

LEXINGTON, MA, UNITED STATES, March 12, 2026 /EINPresswire.com/ -- Cytonome-ST today congratulated Sumitomo Pharma Co., ...

UVeCARE earned major recognition at the Natural Health Readers' Choice Awards 2025, winning the prestigious Natural ...